Ignite Creation Date:
2024-05-11 @ 8:30 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06409728
Status:
RECRUITING
Last Update Posted:
2024-05-10
First Post:
2024-05-07
Brief Title:
Prevalence and Healthcare Consumption of ASD Patients Using French Medico-administrative Data
Sponsor:
University Hospital Montpellier
Organization:
University Hospital Montpellier
Study Overview
Official Title:
Prevalence and Healthcare Consumption of ASD Patients Using French Medico-administrative Data SNDS
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ECO-TSA
Brief Summary:
Autism Spectrum Disorder ASD is one of the neurodevelopmental disorders described in the DSM5 American Psychiatric Association 2013 This heterogeneous syndrome appears in childhood and persists throughout life with different developments from one individual to another It is clinically characterized by the combination of deficits in social communication with restricted and repetitive behaviors The prevalence of ASD has seen a significant increase over the last 10 years with estimates varying greatly from one country to another ranging from 421000 in France to 311000 in Iceland In France prevalence has been estimated by two child disability registers set up in the departments of Haute-Garonne RHE31 Isère Savoie and Haute-Savoie RHEOP but there is no epidemiological surveillance system to estimate the national prevalence of ASD in the general population However the production of reliable epidemiological data at the national and territorial levels is essential for addressing the needs of individuals with ASD and for evaluating public policies
The main objective of our project is to estimate the annual prevalence of ASD in children adolescents and young adults at the national and regional levels using medico-administrative databases SNDS to study its evolution over the period 2010-2019 and its geographical distribution in relation to socio-demographic indicators and healthcare accessibility Our secondary objectives are to validate an algorithm for detecting ASD in the National Health Data System SNDS and to estimate the direct medical costs associated with ASD management
The SNDS databases contain all medical care and treatments reimbursed for Health Insurance beneficiaries provided in the private or public sector A case detection algorithm will be tested and validated on validation samples Then the prevalence of ASD will be estimated taking into account geographical socio-economic and healthcare accessibility indicators in order to study the factors associated with the significant disparity in rates observed in France and abroad An estimate of direct medical costs will be made from the health insurance perspective
Our project therefore proposes the development of reliable indicators on the management of ASD in France with the aim of providing useful indicators and tools for guiding health and disability policies in France promoting the development of appropriate interventions and thus contributing to the improvement of the care and support of individuals with ASD as well as reducing inequalities in access to healthcare for these vulnerable populations
The main objective of our project is to estimate the annual prevalence of ASD in children adolescents and young adults at the national and regional levels using medico-administrative databases SNDS to study its evolution over the period 2010-2019 and its geographical distribution in relation to socio-demographic indicators and healthcare accessibility Our secondary objectives are to validate an algorithm for detecting ASD in the National Health Data System SNDS and to estimate the direct medical costs associated with ASD management
The SNDS databases contain all medical care and treatments reimbursed for Health Insurance beneficiaries provided in the private or public sector A case detection algorithm will be tested and validated on validation samples Then the prevalence of ASD will be estimated taking into account geographical socio-economic and healthcare accessibility indicators in order to study the factors associated with the significant disparity in rates observed in France and abroad An estimate of direct medical costs will be made from the health insurance perspective
Our project therefore proposes the development of reliable indicators on the management of ASD in France with the aim of providing useful indicators and tools for guiding health and disability policies in France promoting the development of appropriate interventions and thus contributing to the improvement of the care and support of individuals with ASD as well as reducing inequalities in access to healthcare for these vulnerable populations
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None